All In Biotech

Drug Trial Radar · NCT00667108

A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance

Last checked: Nov 19, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 784 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

784

Actual

Start

Oct 2004

Primary completion

Not stated

Study completion Jan 2005

Sponsor

Sponsor type
Industry
First posted
Apr 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.

Conditions

  • Transient Insomnia

Interventions

  • GabapentinDrug

    Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

  • GabapentinDrug

    Gabapentin 500 mg oral capsule 30 minutes prior to bedtime

  • PlaceboDrug

    Matched placebo 30 minutes prior to bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjective sleep latencyTime frame: Hour +8

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Anaheim, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Boise, Idaho

  • Pfizer Investigational Site

    Mount Laurel, New Jersey

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Spartanburg, South Carolina

  • Pfizer Investigational Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.